Cadence Pharmaceuticals, (FRA:QEW) Total Liabilities : €40.83 Mil (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Total Liabilities?

Cadence Pharmaceuticals,'s Total Liabilities for the quarter that ended in Dec. 2013 was €40.83 Mil.

Cadence Pharmaceuticals,'s quarterly Total Liabilities declined from Jun. 2013 (€38.39 Mil) to Sep. 2013 (€37.13 Mil) but then increased from Sep. 2013 (€37.13 Mil) to Dec. 2013 (€40.83 Mil).

Cadence Pharmaceuticals,'s annual Total Liabilities increased from Dec. 2011 (€33.71 Mil) to Dec. 2012 (€38.00 Mil) and increased from Dec. 2012 (€38.00 Mil) to Dec. 2013 (€40.83 Mil).

Cadence Pharmaceuticals, Total Liabilities Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Total Liabilities Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Total Liabilities

Get a 7-Day Free Trial

12.01

30.11

33.71

38.00

40.83

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Total Liabilities	Get a 7-Day Free Trial															38.00	36.68	38.39	37.13	40.83

Cadence Pharmaceuticals, Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cadence Pharmaceuticals,'s Total Liabilities for the fiscal year that ended in Dec. 2013 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26.676	+	(13.533	+	0.616
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	40.83

Total Liabilities	=	Total Assets (A: Dec. 2013 )	-	Total Equity (A: Dec. 2013 )
	=	66.286	-	25.461
	=	40.83

Cadence Pharmaceuticals,'s Total Liabilities for the quarter that ended in Dec. 2013 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26.676	+	(13.533	+	0.616
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	40.83

Total Liabilities	=	Total Assets (Q: Dec. 2013 )	-	Total Equity (Q: Dec. 2013 )
	=	66.286	-	25.461
	=	40.83

Cadence Pharmaceuticals, Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, Headlines

No Headlines